Australia markets closed

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
2.93000.0000 (0.00%)
As of 03:59PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 23.25M
Enterprise value -27.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.72
Price/book (mrq)0.53
Enterprise value/revenue -16.55
Enterprise value/EBITDA 0.81

Trading information

Stock price history

Beta (5Y monthly) 0.60
52-week change 3-67.59%
S&P500 52-week change 318.19%
52-week high 39.5300
52-week low 32.6300
50-day moving average 33.0966
200-day moving average 33.4078

Share statistics

Avg vol (3-month) 319.32k
Avg vol (10-day) 312.3k
Shares outstanding 57.94M
Implied shares outstanding 67.94M
Float 84.68M
% held by insiders 134.16%
% held by institutions 127.51%
Shares short (30 Aug 2023) 4213.16k
Short ratio (30 Aug 2023) 413.45
Short % of float (30 Aug 2023) 43.84%
Short % of shares outstanding (30 Aug 2023) 42.69%
Shares short (prior month 30 July 2023) 4183.26k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 318 Mar 2020
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 June 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,529.55%

Management effectiveness

Return on assets (ttm)-30.02%
Return on equity (ttm)-53.76%

Income statement

Revenue (ttm)2.23M
Revenue per share (ttm)0.27
Quarterly revenue growth (yoy)30.80%
Gross profit (ttm)1.52M
EBITDA -34.01M
Net income avi to common (ttm)-31.77M
Diluted EPS (ttm)-4.0500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.85M
Total cash per share (mrq)6.41
Total debt (mrq)346k
Total debt/equity (mrq)0.79%
Current ratio (mrq)8.55
Book value per share (mrq)5.43

Cash flow statement

Operating cash flow (ttm)-27.23M
Levered free cash flow (ttm)-16.64M